ArticleFrontiers in microbiology2026
Zinc gluconate ameliorates antibiotics/PGN-induced intestinal injury via modulating the gut barrier, macrophages immunity and gut microbiota.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to investigate the protective effects of zinc gluconate (ZnG) against antibiotics and peptidoglycan (PGN) induced intestinal injury by targeting gut barrier integrity, macrophage, and gut microbiota homeostasis. Methods: Twenty four C57BL/J mice were randomly divided into four groups: normal group (NC), antibiotic cocktail group (ABX), model group (ABX+PGN), and ZnG treatment group (ZnG+ABX/PGN). An antibiotic associated dysbiosis model was established via oral gavage of an antibiotic cocktail, followed by intraperitoneal injection of PGN (10 mg/kg) to simulate Gram positive (G Results: The results indicated that ZnG significantly increased the body weight of the mice treated with ABX and PGN. It also markedly alleviated pathological and ultrastructural damage in the colon. ZnG improved intestinal permeability by reducing serum diamine oxidase (DAO) levels and restored intestinal integrity by upregulating tight junction proteins (TJs), including zonula occludens-1 (ZO-1), Occludin, and mucin 2 (MUC2). In addition, ZnG modulated the macrophage immunity by regulating the expression of polarization associated proteins (iNOS/ARG-1) and inhibited activation of the TLR2-NF-κB signaling pathway. Microbiota analysis revealed that ZnG increased gut microbial diversity while modulating the microbial community structure and its predicted functional potential in mice. Conclusions: These findings demonstrate that ZnG exhibits therapeutic potential for AAC through modulation of gut microbiota, enhancement of gut barrier, and regulation of immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.